Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531632 · ClinicalTrials.gov registry record · Phase 1
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03531632 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 38 participants.
The verdict
NCT03531632, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of the combination of MGD007 and MGA012 will also be assessed.
Interventions
- BIOLOGICAL MGD007 + MGA012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03531632
The ClinicalTrials.gov registry entry for NCT03531632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGD007 + MGA012 is the first listed.
NCT03531632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03531632 about?
NCT03531632 is a clinical study titled "MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer". The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of the combination of MGD007 and MGA012 will also be assessed.
What is the current status of trial NCT03531632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2018-06-04. Estimated completion is 2020-02-08.
What interventions are being tested in trial NCT03531632?
The interventions under investigation include: MGD007 + MGA012 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03531632?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.